Search
RCT1100
go.drugbank.com/drugs/DB18830InvestigationalRCT1100 is an investigational mRNA-based therapeutic that aims to treat primary ciliary dyskinesia caused by pathogenic mutations in DNAI1.[L50788]
Yeast beta-D-glucan
go.drugbank.com/drugs/DB19271InvestigationalYeast beta-D-glucan is under investigation in clinical trial NCT00632008 (Soluble Beta-glucan (SBG) as Treatment for Diabetic Foot Ulcers).
Synonyms: Beta glucan iv (saccharomyces cerevisiae)Tiazofurine
go.drugbank.com/drugs/DB13243ExperimentalTiazofurine has potential clinical use in cancer treatment as it is a potential inhibitor of Inosine- 5’-monophosphate (IMP) dehydrogenase [A174991].
Cirazoline
go.drugbank.com/drugs/DB09202ExperimentalCirazoline acts on a number of α adrenergic receptors. It is an agonist of α1A, partial agonist of α1B and α1D, and a nonselective antagonist of α2. … It is believed that this combination of properties could make cirazoline an effective vasoconstricting agent.
VT-111
go.drugbank.com/drugs/DB05646InvestigationalVT-111 is a 55 kDa secreted glycoprotein belonging to a superfamily of proteins called SERPINS, which share a general structure and mechanism for proteinase inhibition.
Besifovir dipivoxil
go.drugbank.com/drugs/DB05020InvestigationalBesifovir dipivoxil is a small-molecule orally available inhibitor of the HBV polymerase. The HBV polymerase is the enzyme that catalyzes the production of new RNA from the existing strand of RNA.
Talmapimod
go.drugbank.com/drugs/DB05412InvestigationalIt has shown to be effective to cure inflammatory diseases such as Rheumatoid Arthritis.
Pyrroloquinoline Quinone
go.drugbank.com/drugs/DB03205InvestigationalA pyrrolo-quinoline having two adjacent keto-groups at the 4 and 5 positions and three acidic carboxyl groups. It is a coenzyme of some DEHYDROGENASES. [PubChem]
Demegestone
go.drugbank.com/drugs/DB13857ExperimentalDemegestone is a progesterone receptor agonist that was previously used to treat luteal insufficiency. It was previously marketed in France as Lutionex, but has since been discontinued.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesLuLym-T
go.drugbank.com/drugs/DB17405ExperimentalLuLym-T is an investigational autologous immune cell therapy consisting of activated T Lymphocytes. Developed by Lukas Biomedical, Inc., it is currently being investigated in hepatocellular carcinoma.